Prucalopride Should NOT Be Used for Pediatric Functional Constipation
Prucalopride is not recommended for children with functional constipation, as it has failed to demonstrate efficacy superior to placebo in pediatric populations and is not FDA-approved for use in children. 1, 2
Critical Evidence Against Pediatric Use
FDA Labeling is Clear
The FDA label explicitly states: "It is not known if prucalopride tablet is safe and effective in children" 1. This drug is approved only for adults with chronic idiopathic constipation, making its use in your scenario off-label and unsupported by regulatory approval.
Pediatric Trial Data Shows No Benefit
The pivotal pediatric trial (n=213 children, ages 6 months to 18 years) demonstrated that prucalopride was no more effective than placebo 2. The response rate was essentially identical:
- Prucalopride: 17.0% responders
- Placebo: 17.8% responders
This high-quality, multicenter, randomized, placebo-controlled trial specifically evaluated children with functional constipation who had failed conventional therapy—exactly your clinical scenario 2.
Recent Systematic Reviews Confirm Lack of Efficacy
A 2025 Lancet systematic review and meta-analysis found moderate certainty evidence that prucalopride results in little or no difference compared to placebo in defecation frequency (MD 0.50,95% CI -0.06 to 1.06), treatment success (RR 0.96,95% CI 0.53 to 1.72), and adverse events (RR 1.15,95% CI 0.94 to 1.39) 3.
A 2024 Cochrane review similarly concluded that prucalopride probably results in little or no difference in outcomes compared to placebo in children with intractable constipation 4.
Safety Concerns in Pediatric Populations
Neuropsychiatric Adverse Effects
The FDA label carries a black box-level warning about suicidal ideation and behavior, mood changes, and depression 1. While the drug was generally well-tolerated in the pediatric trial, a 2025 case report documented acute-onset visual and auditory hallucinations with suicidal ideation in a 15-year-old after a single 2 mg dose 5. This is particularly concerning in adolescents with any psychiatric history.
Common Side Effects
Treatment-emergent adverse events occurred in 69.8% of children on prucalopride versus 60.7% on placebo 2. The most common include headache, nausea, diarrhea, abdominal pain, and fatigue 1.
What Should You Do Instead?
Optimize Polyethylene Glycol (PEG) Therapy
The 2025 Lancet meta-analysis provides moderate certainty evidence that PEG is more effective than placebo (RR 1.74,95% CI 1.25-2.41) and low certainty evidence that PEG may be more effective than lactulose (RR 1.35,95% CI 1.11-1.64) 3.
Before abandoning PEG:
- Ensure adequate dosing: You mention 0.7 g/kg/day, but doses up to 1.5 g/kg/day may be needed
- Verify compliance and proper mixing
- Consider split dosing (twice daily rather than once daily)
- Ensure adequate duration of trial (at least 2-3 months at optimal dose)
Consider Alternative Evidence-Based Options
While the 2023 AGA/ACG guideline discusses prucalopride for adults with chronic idiopathic constipation 6, it does not address pediatric populations. For children who have truly failed optimized PEG and lactulose:
- Magnesium-based laxatives (magnesium oxide or hydroxide)
- Stimulant laxatives (bisacodyl, senna) for rescue or short-term use
- Behavioral interventions and toilet training optimization
- Referral to pediatric gastroenterology for consideration of other interventions
Clinical Pitfalls to Avoid
- Do not assume failure of PEG without optimizing dose and ensuring compliance
- Do not use prucalopride off-label in children based on adult data—the pediatric trial was definitively negative
- Be especially cautious about neuropsychiatric effects in adolescents with any mental health history
- Remember that "intractable" constipation often reflects inadequate optimization of first-line therapies rather than true treatment failure
Bottom Line
Prucalopride has no role in pediatric functional constipation. The evidence is clear and consistent: it does not work better than placebo in children, it is not FDA-approved for this population, and it carries neuropsychiatric risks. Focus on optimizing PEG dosing and exploring other evidence-based alternatives before considering any off-label prokinetic agents.